BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19770366)

  • 1. Thalidomide maintenance in multiple myeloma: certainties and controversies.
    Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P
    J Clin Oncol; 2009 Nov; 27(32):e186-7; author reply e188. PubMed ID: 19770366
    [No Abstract]   [Full Text] [Related]  

  • 2. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hematopoietic stem cell transplantation for multiple myeloma].
    Kanda Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1420-6. PubMed ID: 19915350
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant.
    Stewart AK; Chen CI; Howson-Jan K; White D; Roy J; Kovacs MJ; Shustik C; Sadura A; Shepherd L; Ding K; Meyer RM; Belch AR
    Clin Cancer Res; 2004 Dec; 10(24):8170-6. PubMed ID: 15623591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
    Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
    Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?
    van Rhee F
    Nat Clin Pract Oncol; 2008 Feb; 5(2):70-1. PubMed ID: 17984985
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
    Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IG; Martin H; Hoelzer D; Ho AD; Lokhorst HM; ;
    Ann Hematol; 2003 Oct; 82(10):654-9. PubMed ID: 12845480
    [No Abstract]   [Full Text] [Related]  

  • 13. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
    Abdelkefi A; Torjman L; Ben Romdhane N; Ladeb S; El Omri H; Ben Othman T; Elloumi M; Bellaj H; Lakhal A; Jeddi R; Aissaouï L; Saad A; Hsaïri M; Boukef K; Dellagi K; Ben Abdeladhim A
    Bone Marrow Transplant; 2005 Aug; 36(3):193-8. PubMed ID: 15968290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients.
    Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R
    Haematologica; 2003 May; 88(5):597-9. PubMed ID: 12745281
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing landscape of myeloma therapy.
    Cavo M; Baccarani M
    N Engl J Med; 2006 Mar; 354(10):1076-8. PubMed ID: 16525146
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
    Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
    Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
    [No Abstract]   [Full Text] [Related]  

  • 18. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
    Dasanu CA; Reale MA; Bauer F
    Leuk Res; 2010 Jul; 34(7):e178-80. PubMed ID: 20079532
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
    Zomas A; Anagnostopoulos N; Dimopoulos MA
    Bone Marrow Transplant; 2000 Jun; 25(12):1319-20. PubMed ID: 10871741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide.
    Witzens M; Moehler T; Neben K; Fruehauf S; Hartschuh W; Ho AD; Goldschmidt H
    Ann Hematol; 2004 Jul; 83(7):467-70. PubMed ID: 14625789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.